See AXA1125’s potential impact on Long COVID
See how compositions of endogenous metabolic modulators (EMMs) can be utilized for complex diseases
Pioneering a new approach to treating complex diseases using Endogenous Metabolic Modulators (EMMs).
Endogenous Metabolic Modulators, or EMMs, are a critical set of molecules that are fundamental to biology. They serve as master regulators and signaling agents for metabolic pathways throughout the body. EMMs encompass a broad set of molecular families, including amino acids and their derivatives.
We combine our deep understanding of metabolic pathways, our unique EMM-focused database and recent advances in technology and systems biology to design novel product candidates with the potential to have a profound impact on complex diseases and support health.
The clinical data we have generated to date support the potential for our therapeutic product candidates to simultaneously influence multiple biologies relevant to complex diseases with a favorable safety profile. Our lead product candidates are for liver diseases.
Axcella Long COVID Treatment Helps Some Patients in Small Trial
Reuters, August, 2022
Axcella Previews Long COVID Registrational Trial Plans in UK and US
Clinical Trials Arena, August, 2022
Axcella’s CEO Knows People Are Tired of the Pandemic. But Long COVID Patients Need Help, too.
Fierce Biotech, June, 2022
Feeling Fatigued? Drug Maker Eyes Long COVID Symptoms with New Treatment
NBC New York, June, 2022
Drugmakers, Scientists Begin the Hunt for Long COVID Treatments
Reuters, March, 2022
UK Launches Trial of Drug to Tackle Fatigue in Long COVID Patients
The Guardian, November, 2021
Flagship-founded Axcella to Test Midstage NASH Drug in Patients with Long COVID in Phase 2a Trial
Fierce Biotech, October, 2021
We have built a strong leadership team with deep biopharma expertise.
Find out about Axcella’s latest accomplishments and upcoming events.
We value bright minds, collaborative approaches and energetic spirits.
We are publishing innovative research and presenting at leading conferences.